SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Elixir Medical Announces First Commercial Implant Of The DESolve® Novolimus Eluting Coronary Scaffold System in Europe

[January 15, 2014]

Elixir Medical Announces First Commercial Implant Of The DESolve® Novolimus Eluting Coronary Scaffold System in Europe

SUNNYVALE, Calif. --(Business Wire)--

Marking a milestone in the evolution of fully-bioresorbable drug-eluting scaffolds for interventional cardiology, the first commercial implant of Elixir Medical's CE Mark-approved DESolve Novolimus Eluting Coronary Scaffold was performed in Germany by Professor Dr. med. Holger Nef, Head of the Cardiac Catheterization Laboratory, University Hospital Giessen, Giessen, Germany.

Elixir's fully bioresorbable DESolve scaffold for coronary artery disease restores blood flow to the heart like metallic stents, but then dissolves to leave behind a treated artery that can function and move more naturally because it is free of a permanent implant. Developed from a proprietary and proven poly-L Lactide (PLLA)-based polymer, DESolve provides optimal strength and support to the artery while delivering the novel anti-proliferative drug, Novolimus.

The unique advantages of the DESolve scaffold system include (a) maintaining radial strength and vessel support for the necessary period of vessel healing while degrading in one year; (b) increasing lumen area within six months; (c) self-apposing to the vessel wall up to the nominal deployed diameter; and (d) providing a wide margin of expansion.

"The fully bioresorbable DESolve System is easy to deliver. The acute performance of the scaffold demonstrated excellent stent apposition to the vessel wall and low recoil, and the patient is doing well," said Professor Nef. Professor Dr. med. Christian Hamm, Director of Cardiology at University Hospital Giessen further commented, "I am confident that Elixir's scaffold system will drive forward the field of vascular intervention."

Developing an optimal bioresorbable scaffold had long been a challenge in the coronary vascular industry because it requires a level of strength and support that previously only permanent metallic stents had been able to provide while degrading in a tmely manner and maintaining excellent clinical outcomes. The DESolve Novolimus Eluting Bioresorbable Coronary Scaffold overcomes these challenges and achieves vascular restoration within six months. Elixir's DESolve accomplishes this objective years sooner than competitive scaffolds.


"Elixir's DESolve has excellent clinical trial data to support its use. It is the first scaffold to degrade in one year, demonstrate lumen area increase within six months, and maintain the lumen area beyond one year," said Stefan Verheye, M.D., Ph.D., ZNA Middleheim Hospital, Antwerp, Belgium, and Co-Principal Investigator of the DESolve Nx Trial. "These key differentiating features will create a paradigm shift in the treatment of patients with cardiovascular disease."

The DESolve Nx pivotal trial enrolled 126 patients at 13 centers in Europe, Brazil and New Zealand. Excellent 1-year safety and efficacy results for the DESolve Novolimus Eluting Coronary Scaffold System had been announced at the Transcatheter Therapeutics 2013 scientific conference in San Francisco in October 2013.

At one year, the DESolve Nx trial demonstrated a low MACE (Major Adverse Cardiac Events) rate of 5.69% with no definite scaffold thrombosis. Results using MSCT (Multi Slice Coherence Tomography), a noninvasive imaging modality to visualize coronary arteries and the manifestations of coronary artery disease, demonstrated that the lumen area measurements of treated vessels at one year were maintained to the results that were observed at 6 months using other imaging modalities.

"Elixir is proud to fulfill its commitment of providing the broadest and most innovative product portfolio for cardiologists to address their patients' needs," said Motasim Sirhan, President and Chief Executive Officer of Elixir Medical. "The fully bioresorbable DESolve Scaffold System holds the promise of transforming the interventional cardiology industry by raising the bar in clinical outcomes and leaving no permanent implant behind."

The fully bioresorbable DESolve Novolimus Eluting Scaffold System roll out will begin at initial centers in Europe. The scaffold is currently available in diameters of 3.0, 3.25 and 3.5 mm and lengths of 14, 18 and 28 mm. Additional sizes will be available in 2014.

About Elixir Medical

Elixir Medical is the only company with three CE Mark-approved drug-eluting systems spanning all market segments: the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold system, the DESyne® BD Novolimus Eluting Coronary Stent System (with biodegradable polymer), and the DESyne® Novolimus Eluting Coronary Stent System (with durable polymer). The company has also received US Food and Drug Administration's IDE (Investigational Device Exemption) approval to commence the EXCELLA III Clinical Trial in the United States with Elixir's durable polymer Novolimus Eluting Coronary Stent System.

Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffold are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit www.elixirmedical.com.


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved | Privacy Policy